TAIPEI, Taiwan, Feb. 16 /Xinhua-PRNewswire/ -- TaiGen Biotechnology announced today that Mr. William Keller has been elected to the Board.
“We are honored to have Mr. Keller join the Board of Directors,” said Ming-Chu Hsu, Ph.D., the President & CEO of TaiGen Biotechnology. “His deep industry knowledge and 12-year tenure as the head of Roche China and Hong Kong will provide TaiGen with invaluable insights and facilitate TaiGen’s development strategy in the fast growing China market.’'
Mr. Keller spent more than 30 years of his career at Roche. Prior to joining the Board of Directors at TaiGen Biotechnology, he was the General Manager of Roche China, Ltd., where he formulated and developed Roche strategy for China and Hong Kong. Under his leadership, Roche became one of the leading pharmaceutical companies in China. Mr. Keller first joined Roche in 1972. Over the years, he was given increasing responsibilities and rose through the ranks at Roche. He was promoted to the Deputy General Manager of Roche Brazil and later, the General Manager of Roche Columbia before he became the General Manager of Roche China.
About TaiGen Biotechnology
TaiGen Biotechnology is a privately held pharmaceutical R&D company founded in 2001 and headquartered in Taiwan. The company focuses on developing innovative therapeutic products to treat cancer, infectious diseases and diabetic complications. In addition to its own internal research programs, the company is actively pursuing in-licensing late-stage development products for early commercialization in Asia. Currently, the company’s development products include an antibacterial TG-873870 completed phase 1 trials and entering phase 2 trials, and IND filing for a compound to treat critical limb ischemia in 2H/2006. TaiGen has operations in Taiwan and China. Please visit http://www.taigenbiotech.com for additional information.
TaiGen Contact Dr. Stephen Ip, Sr. VP Global Business Development Tel: +886-2-2790-1861 Email: Stephenip@taigenbiotech.com.tw
TaiGen Biotechnology
CONTACT: Dr. Stephen Ip of TaiGen Biotechnology, +886-2-2790-1861, orStephenip@taigenbiotech.com.tw
